English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 29 August 2019, 10:46 HKT/SGT
Share:
    

Source: Eisai
Eisai to Launch New "Etak Antimicrobial Wet Wipes" With One Week Lasting Antimicrobial Action
Alcohol-Free Wipe for Eliminating Viruses and Bacteria on Personal Belongings

TOKYO, Aug 29, 2019 - (JCN Newswire) - Eisai Co., Ltd. will launch ETAK( Antimicrobial Wet Wipes (classified as miscellaneous goods) containing long-acting antimicrobial agent ETAK on August 29, 2019 at pharmacies and drugstores countrywide.

ETAK, the main ingredient used in the product, is a long-acting antimicrobial agent developed by Professor Hiroki Nikawa of the Department of Oral Biology and Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. An adhesive component of ETAK chemically binds the antimicrobial component to the area wiped with ETAK Antimicrobial Wet Wipes, preserving an antimicrobial effect that lasts for one week.

Eliminating virus and bacteria is a familiar and highly interested theme for consumers, especially mothers with small children.

There were many requests from mothers with small children such as "I want to use ETAK product not only inside the house but also the outside" and "I want to use ETAK product conveniently to the difficult to spray area. In response to these requests, ETAK Antimicrobial Wet Wipes has been commercialized. ETAK Antimicrobial Wet Wipes is alcohol-free so that it is easy to use for families with small children, and it can be used for elimination of viruses and bacteria on personal belongings as well as for cleaning hands and fingertips. In addition, wiping with this product can have antimicrobial barrier for personal belongings and prepare for virus and bacteria. The effect remains even if the area is wiped with water."

As the ETAK brand, containing long-acting antimicrobial agent ETAK, Eisai is marketing ETAK Antimicrobial Spray, a spray for mouth masks, which eliminates viruses and bacteria for 24 hours and ETAK Antimicrobial Spray alpha which can be used for a variety of lifestyle supplies including fabrics such as clothes and stuffed toys as well as kitchenware.

The addition of ETAK Antimicrobial Wet Wipes to the product lineup of ETAK brand will propose new options for elimination of viruses and bacteria as well as antimicrobial action, and we will contribute to further improvement of benefits of consumers who wish to keep those viruses and bacteria at bay.

*This product is not effective on all types of virus and bacteria.
*This product is not a pharmaceutical product nor a quasi-pharmaceutical product.
*ETAK is a registered trademark of CampusMedico Co., Ltd.

About Long-acting Antimicrobial Agent ETAK

ETAK was developed by Professor Hiroki Nikawa of the Department of Oral Biology and Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. It is a patented long-acting antimicrobial agent (patent number: 4830075) that combines quaternary ammonium salts, which are also included in hand sanitizers and oral cleansing agents used by dentists, with a silane analogue, an immobilizing agent that functions as an adhesive. ETAK chemically binds the antimicrobial component to the spray area, thereby preserving the antimicrobial effect on the surface of the target object.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120


Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Releated News
Oct 23, 2019 10:13 HKT/SGT
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
Oct 23, 2019 10:00 HKT/SGT
バイオジェンとエーザイ、アデュカヌマブ 臨床第III相試験で得られた大規模データセットの新たな解析結果に基づき、アルツハイマー病を対象とした新薬承認申請を予定
Oct 16, 2019 11:00 HKT/SGT
エーザイ、抗てんかん剤「フィコンパ(R)」部分てんかん併用療法に係る適応で中国当局より新薬承認を取得
Oct 15, 2019 20:24 HKT/SGT
Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China
Oct 1, 2019 10:46 HKT/SGT
Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress
More news >>
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575